194539-38-3

Upstream product

• 194539-36-1 (1S,2S)-2-(2,4-Dinitro-phenylamino)-1-phenyl-3-((3aS,4R,9aR,9bS)-2,2,8,8-tetramethyl-4,6,9a,9b-tetrahydro-3aH-[1,3]dioxolo[4',5':3,4]benzo[1,2-d][1,3]dioxin-4-ylamino)-propan-1-ol 
• 194539-31-6 Methanesulfonic acid (2S,3S)-2-(2,4-dinitro-phenylamino)-3-hydroxy-3-phenyl-propyl ester 
• 194539-30-5 (1S,2S)-2-(2,4-Dinitro-phenylamino)-1-phenyl-propane-1,3-diol 
• 194539-33-8 (S)-[(S)-1-(2,4-Dinitro-phenyl)-aziridin-2-yl]-phenyl-methanol 
• 28143-91-1 (1S,2S)-2-amino-1-phenyl-1,3-diol 
• 194539-37-2 (1S,2S,3R,6R)-6-[(2S,3S)-2-(2,4-Dinitro-phenylamino)-3-hydroxy-3-phenyl-propylamino]-4-hydroxymethyl-cyclohex-4-ene-1,2,3-triol 

Downstream Products

• 194539-39-4 Decanoic acid ((2S,3S)-2-decanoylamino-3-hydroxy-3-phenyl-propyl)-((1R,4R,5S,6S)-4,5,6-trihydroxy-3-hydroxymethyl-cyclohex-2-enyl)-amide 

Relevant academic research and scientific papers

Synthesis and biological evaluation of four stereoisomers of PDMP-analogue, N-(2-decylamino-3-hydroxy-3-phenylprop- 1-yl)-β-valienamine, and related compounds

All stereoisomers with regard to C-1 and 2 of 1-phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP) analogue containing unsaturated (β-valienamine) and saturated 5a-carba-β-D-glucopyranosylamine (β-validamine) residues in place of morpholine moiety were synthesized. Although PDMP is a potent and specific glucosylceramide synthase inhibitor, the former valienamine analogues (4a-d) have been shown to be strong glucocerebrosidase inhibitors (IC50 3-7 x10-7 M). The latter validamine analogues (5a-d) were also moderate glucocerebrosidase inhibitors (IC50 5-20 x 10-6 M). A series of compounds synthesized lacked an inhibitory potency against the glucosyltransferase at all. Whereas the analogue 6a composed of epimeric α-valienamine residue did not possess any potency against both enzymes.